The facility is designed to be a comprehensive production base for the entire range of hypoglycemic products, focusing on the manufacture of biologics and chemicals. These medicines are intended for widespread distribution to the global market. The company has officially started commercial production of chemical drugs in April 2024. Additionally, the biopharmaceutical division has completed the process validation for several varieties of insulin.

Learn More: www.ganlee.com

Contact with Us: info@ganlee.com